Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Immune test may fine-tune virus prevention in transplant patients

NCT ID NCT06449586

First seen Jan 10, 2026 · Last updated May 01, 2026 · Updated 16 times

Summary

This study tests whether a blood test that measures CMV-specific immunity can help doctors decide how long to use the antiviral drug letermovir after a stem cell transplant. The goal is to prevent late-onset CMV infection, a common and serious complication. The trial involves 250 adults receiving their first transplant and will compare infection rates between standard care and immune-guided treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Ruijin Hospital of Shanghai Jiaotong University

    Shanghai, Shanghai Municipality, China

  • Ruijin Hospital, Shanghai JiaoTong University School of Medicine

    Shanghai, China

  • Shanghai Liquan Hospital

    Shanghai, China

  • The First Hospital of Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • Tongji Hospital of Huazhong University of Science and Technology, Wuhan

    Wuhan, Hubei, China

Conditions

Explore the condition pages connected to this study.